Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia: A two year longitudinal study
An earlier study (Study 1: 14 months duration) showed that the PAT (an auditory attention task) is sensitive to changes of clinical state in chronic schizophrenia and is able to predict hospital discharge. The newly presented study (Study 2: 12 months duration) investigated the effects of increasing...
Gespeichert in:
| Veröffentlicht in: | Schizophrenia research 1993-06, Vol.10 (1), p.51-59 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 59 |
|---|---|
| container_issue | 1 |
| container_start_page | 51 |
| container_title | Schizophrenia research |
| container_volume | 10 |
| creator | Pigache, R.M. |
| description | An earlier study (Study 1: 14 months duration) showed that the PAT (an auditory attention task) is sensitive to changes of clinical state in chronic schizophrenia and is able to predict hospital discharge. The newly presented study (Study 2: 12 months duration) investigated the effects of increasing the dose of chlorpromazine (CPZ) stepwise (double-blind) to between 900 mg and 1800 mg per day, in 10 of the original 20 patients. Measurements were made fortnightly throughout both studies and the data were depicted continuously for each patient. Study 2 showed that a 300% increase of CPZ dose neither improved nor impaired PAT performance. Also, the addition of orphenadrine 300 mg per day had no significant effect on performance. Four types of relapse were detected. The first was induced by placebo substitution for CPZ and recovered when the drug was reinstated. The remaining types of relapse were all resistant to CPZ and comprised: a long-period pattern with a spontaneous reversal; unremitting deterioration; and a short-period pattern of labile relapse and recovery. |
| doi_str_mv | 10.1016/0920-9964(93)90076-U |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_75942080</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>092099649390076U</els_id><sourcerecordid>75942080</sourcerecordid><originalsourceid>FETCH-LOGICAL-e205t-86e097f8754124580f29ff1878bfbf3b48badbce52505fa06119ba1c207e05a33</originalsourceid><addsrcrecordid>eNo9kV1rFDEUhoModa3-A4VciCh09CSZzEx6ISylfkBBL7rXIZM56UZmkjGZVba_wp9sdrv06hw4Dwfe9yHkNYOPDFjzCRSHSqmmfq_EBwXQNtXmCVkx2YqKS1BPyeoReU5e5PwLAJiE9oycdaJRXPAV-XftHNol0-joPBqLfbygMc1bDGZIPuAFNWGgyWcf7ugQMx5Rux0LlOJk7o9MDPTn-pbOmFxMkwkWqQ-FSjF4S7Pd-vs4bxMGby7pmi5_I92jSXSM4c4vu8EHM9Jclv1L8syZMeOr0zwnmy_Xt1ffqpsfX79frW8q5CCXqmsQVOu6VtaM17IDx5VzrGu73vVO9HXXm6G3KEsT0hloGFO9YZZDiyCNEOfk3cPfkuL3DvOiJ58tjqMJGHdZt1LVHDoo4JsTuOsnHPSc_GTSXp8qLPe3p7vJ1owulfQ-P2J1WyshWME-P2BYQv3xmHS2HktRg09FgB6i1wz0waw-aNMHbVoJfTSrN-I_ZhyWbw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75942080</pqid></control><display><type>article</type><title>Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia: A two year longitudinal study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Pigache, R.M.</creator><creatorcontrib>Pigache, R.M.</creatorcontrib><description>An earlier study (Study 1: 14 months duration) showed that the PAT (an auditory attention task) is sensitive to changes of clinical state in chronic schizophrenia and is able to predict hospital discharge. The newly presented study (Study 2: 12 months duration) investigated the effects of increasing the dose of chlorpromazine (CPZ) stepwise (double-blind) to between 900 mg and 1800 mg per day, in 10 of the original 20 patients. Measurements were made fortnightly throughout both studies and the data were depicted continuously for each patient. Study 2 showed that a 300% increase of CPZ dose neither improved nor impaired PAT performance. Also, the addition of orphenadrine 300 mg per day had no significant effect on performance. Four types of relapse were detected. The first was induced by placebo substitution for CPZ and recovered when the drug was reinstated. The remaining types of relapse were all resistant to CPZ and comprised: a long-period pattern with a spontaneous reversal; unremitting deterioration; and a short-period pattern of labile relapse and recovery.</description><identifier>ISSN: 0920-9964</identifier><identifier>EISSN: 1573-2509</identifier><identifier>DOI: 10.1016/0920-9964(93)90076-U</identifier><identifier>PMID: 8369232</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Adult ; Attention - drug effects ; Biological and medical sciences ; Chlorpromazine - administration & dosage ; Chronic Disease ; Dominance, Cerebral - drug effects ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Therapy, Combination ; Humans ; Length of Stay ; long-term study ; Longitudinal Studies ; Male ; Medical sciences ; Middle Aged ; Neuroleptic ; Neuropharmacology ; Orphenadrine - administration & dosage ; Pharmacology. Drug treatments ; Pigache Attention Task (PAT) ; Psychiatric Status Rating Scales ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Reaction Time - drug effects ; Recurrence ; Schizophrenia - drug therapy ; Schizophrenic Psychology ; Speech Perception - drug effects</subject><ispartof>Schizophrenia research, 1993-06, Vol.10 (1), p.51-59</ispartof><rights>1993</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0920-9964(93)90076-U$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4749331$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8369232$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pigache, R.M.</creatorcontrib><title>Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia: A two year longitudinal study</title><title>Schizophrenia research</title><addtitle>Schizophr Res</addtitle><description>An earlier study (Study 1: 14 months duration) showed that the PAT (an auditory attention task) is sensitive to changes of clinical state in chronic schizophrenia and is able to predict hospital discharge. The newly presented study (Study 2: 12 months duration) investigated the effects of increasing the dose of chlorpromazine (CPZ) stepwise (double-blind) to between 900 mg and 1800 mg per day, in 10 of the original 20 patients. Measurements were made fortnightly throughout both studies and the data were depicted continuously for each patient. Study 2 showed that a 300% increase of CPZ dose neither improved nor impaired PAT performance. Also, the addition of orphenadrine 300 mg per day had no significant effect on performance. Four types of relapse were detected. The first was induced by placebo substitution for CPZ and recovered when the drug was reinstated. The remaining types of relapse were all resistant to CPZ and comprised: a long-period pattern with a spontaneous reversal; unremitting deterioration; and a short-period pattern of labile relapse and recovery.</description><subject>Adult</subject><subject>Attention - drug effects</subject><subject>Biological and medical sciences</subject><subject>Chlorpromazine - administration & dosage</subject><subject>Chronic Disease</subject><subject>Dominance, Cerebral - drug effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Length of Stay</subject><subject>long-term study</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuroleptic</subject><subject>Neuropharmacology</subject><subject>Orphenadrine - administration & dosage</subject><subject>Pharmacology. Drug treatments</subject><subject>Pigache Attention Task (PAT)</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Reaction Time - drug effects</subject><subject>Recurrence</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenic Psychology</subject><subject>Speech Perception - drug effects</subject><issn>0920-9964</issn><issn>1573-2509</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kV1rFDEUhoModa3-A4VciCh09CSZzEx6ISylfkBBL7rXIZM56UZmkjGZVba_wp9sdrv06hw4Dwfe9yHkNYOPDFjzCRSHSqmmfq_EBwXQNtXmCVkx2YqKS1BPyeoReU5e5PwLAJiE9oycdaJRXPAV-XftHNol0-joPBqLfbygMc1bDGZIPuAFNWGgyWcf7ugQMx5Rux0LlOJk7o9MDPTn-pbOmFxMkwkWqQ-FSjF4S7Pd-vs4bxMGby7pmi5_I92jSXSM4c4vu8EHM9Jclv1L8syZMeOr0zwnmy_Xt1ffqpsfX79frW8q5CCXqmsQVOu6VtaM17IDx5VzrGu73vVO9HXXm6G3KEsT0hloGFO9YZZDiyCNEOfk3cPfkuL3DvOiJ58tjqMJGHdZt1LVHDoo4JsTuOsnHPSc_GTSXp8qLPe3p7vJ1owulfQ-P2J1WyshWME-P2BYQv3xmHS2HktRg09FgB6i1wz0waw-aNMHbVoJfTSrN-I_ZhyWbw</recordid><startdate>199306</startdate><enddate>199306</enddate><creator>Pigache, R.M.</creator><general>Elsevier B.V</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>199306</creationdate><title>Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia: A two year longitudinal study</title><author>Pigache, R.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e205t-86e097f8754124580f29ff1878bfbf3b48badbce52505fa06119ba1c207e05a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Adult</topic><topic>Attention - drug effects</topic><topic>Biological and medical sciences</topic><topic>Chlorpromazine - administration & dosage</topic><topic>Chronic Disease</topic><topic>Dominance, Cerebral - drug effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Length of Stay</topic><topic>long-term study</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuroleptic</topic><topic>Neuropharmacology</topic><topic>Orphenadrine - administration & dosage</topic><topic>Pharmacology. Drug treatments</topic><topic>Pigache Attention Task (PAT)</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Reaction Time - drug effects</topic><topic>Recurrence</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenic Psychology</topic><topic>Speech Perception - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pigache, R.M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Schizophrenia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pigache, R.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia: A two year longitudinal study</atitle><jtitle>Schizophrenia research</jtitle><addtitle>Schizophr Res</addtitle><date>1993-06</date><risdate>1993</risdate><volume>10</volume><issue>1</issue><spage>51</spage><epage>59</epage><pages>51-59</pages><issn>0920-9964</issn><eissn>1573-2509</eissn><abstract>An earlier study (Study 1: 14 months duration) showed that the PAT (an auditory attention task) is sensitive to changes of clinical state in chronic schizophrenia and is able to predict hospital discharge. The newly presented study (Study 2: 12 months duration) investigated the effects of increasing the dose of chlorpromazine (CPZ) stepwise (double-blind) to between 900 mg and 1800 mg per day, in 10 of the original 20 patients. Measurements were made fortnightly throughout both studies and the data were depicted continuously for each patient. Study 2 showed that a 300% increase of CPZ dose neither improved nor impaired PAT performance. Also, the addition of orphenadrine 300 mg per day had no significant effect on performance. Four types of relapse were detected. The first was induced by placebo substitution for CPZ and recovered when the drug was reinstated. The remaining types of relapse were all resistant to CPZ and comprised: a long-period pattern with a spontaneous reversal; unremitting deterioration; and a short-period pattern of labile relapse and recovery.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>8369232</pmid><doi>10.1016/0920-9964(93)90076-U</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0920-9964 |
| ispartof | Schizophrenia research, 1993-06, Vol.10 (1), p.51-59 |
| issn | 0920-9964 1573-2509 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75942080 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Attention - drug effects Biological and medical sciences Chlorpromazine - administration & dosage Chronic Disease Dominance, Cerebral - drug effects Dose-Response Relationship, Drug Double-Blind Method Drug Therapy, Combination Humans Length of Stay long-term study Longitudinal Studies Male Medical sciences Middle Aged Neuroleptic Neuropharmacology Orphenadrine - administration & dosage Pharmacology. Drug treatments Pigache Attention Task (PAT) Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Reaction Time - drug effects Recurrence Schizophrenia - drug therapy Schizophrenic Psychology Speech Perception - drug effects |
| title | Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia: A two year longitudinal study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T06%3A26%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20placebo,%20orphenadrine,%20and%20rising%20doses%20of%20chlorpromazine,%20on%20PAT%20performance%20in%20chronic%20schizophrenia:%20A%20two%20year%20longitudinal%20study&rft.jtitle=Schizophrenia%20research&rft.au=Pigache,%20R.M.&rft.date=1993-06&rft.volume=10&rft.issue=1&rft.spage=51&rft.epage=59&rft.pages=51-59&rft.issn=0920-9964&rft.eissn=1573-2509&rft_id=info:doi/10.1016/0920-9964(93)90076-U&rft_dat=%3Cproquest_pubme%3E75942080%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75942080&rft_id=info:pmid/8369232&rft_els_id=092099649390076U&rfr_iscdi=true |